Skip to main content
Clinical Trials/NCT02663245
NCT02663245
Completed
Not Applicable

INTEGRA Study: Intervention in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control on Primary Health Care.

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina1 site in 1 country564 target enrollmentDecember 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Enrollment
564
Locations
1
Primary Endpoint
Glycaemic control measured by HbA1c
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The intensification of the management for the control of glycaemia and other risk factors in patients with type 2 diabetes (DM2) results in a reduction of diabetes-related complications.

The strategy to increase the competences of primary care professionals to improve health care has been mainly prompted by the current context of limited resources and restricted access to specialty care.

This study aims to evaluate the effectiveness and cost-effectiveness of an integral intervention carried out by primary care professionals with the following components:

  1. detection of patients with poor diabetic control;
  2. introduction of a specific consultation on diabetes followed by virtual and telephone specialist support;
  3. introduction of other measures to overcome patients and professionals barriers to treatment.

The main objective of the study is to determine if glycaemic control as measured by the mean concentration of HbA1c of poorly controlled patients improves when these patients are evaluated and treated in primary care under the integral strategy proposed in this study. The INTEGRA project also includes Phase 1 (qualitative research study), which is aimed at identifying viable strategies to suppress barriers to treatment; these strategies have been included to the intervention study (phase 2).

Phase 2 is a controlled, quasi-experimental intervention that involves 9 primary care centres of 3 regions (Lleida, Girona, Barcelona). The participants are patients with DM2 with poor glycaemic control that meet all the inclusion criteria and sign the informed consent. The intervention study will have three arms: (1) Control Group; (2) Intervention Group 1 (diabetes specific consultation + additional measures originated in phase 1; and (3) Intervention Group 2 (additional measures originated in phase 1).

Phase 1 has been conducted during the last 6 months previous to the initiation of the proposed intervention study and consisted of a qualitative design (individualized interviews with randomly selected patients in each of the participating centers); this qualitative study has contributed to design the final intervention applied on phase 2, particularly, implementing additional measures as coaching sessions to health professionals of the participating centers and automated messaging to patients with reminder and motivational objectives.

Phase 2 consists of a recruitment period of 6 months, followed by a 12-month follow-up for each patient

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
December 31, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Responsible Party
Principal Investigator
Principal Investigator

Àngels Molló

MD, PhD

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Glycaemic control measured by HbA1c

Time Frame: 12 months

Secondary Outcomes

  • evaluation of therapeutic inertia: specific questionnaire created by Redgedaps(12 months)
  • evaluation of patient satisfaction using spanish version of diabetes treatment satisfaction questionnaire (DTSQ)(12 months)
  • lipid profile control as measured by the mean concentration of LDL-cholesterol, non-HDL cholesterol and triglycerides(12 months)
  • measurement of systolic blood pressure and of diastolic blood pressure(12 months)
  • control of chronic complications associated with type 2 diabetes according to the protocol of the CIH(12 months)
  • direct health costs of type 2 diabetic patients(12 months)
  • control of risk factors, smoking and exercise: Patient Activation Measure questionnaire(12 months)
  • evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL)(12 months)

Study Sites (1)

Loading locations...

Similar Trials